Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

References

• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870-84
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-24
   PubMed Web of Science ®Google Scholar
• Bachelot T, McCool R, Duffy S, et al. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat 2014;143:125-33
   PubMed Web of Science ®Google Scholar
• Cope S, Zhang J, Smiechowski B, et al. Comparative Efficacy of Everolimus and Exemestane versus Chemotherapy for Advanced Breast Cancer in terms of Progression-Free Survival. In: 2013 San Antonio Breast Cancer Symposium. San Antonio, TX, 2013. Available at: http://www.abstracts2view.com/sabcs13/viewp.php?nu=P6-10-03 Last accessed July 6, 2015.
   Google Scholar
• Xie J, Hao Y, Li N, et al. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin 2015: published online 13 May 2015, doi: 10.1185/03007995.2015.1021906
   Google Scholar
• Pouget M, Planchat E, Abrial C, et al. Everolimus plus hormonotherapy (HT) induces survival gain in late metastatic breast cancer (MBC) after progression: could this line be better than a late new chemotherapy (CT) line? Ann Oncol (2014) 25 (suppl 4): iv132. doi: 10.1093/annonc/mdu329.50 https://www.webges.com/cslide/library/esmo/browse/search/oRS#9faC02xU
   Google Scholar
• Beck JT, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 2014;143:459-67
   PubMed Web of Science ®Google Scholar
• Li N, Hao Y, Xie J, et al. Everolimus-based therapy versus chemotherapy among patients with HR+/HER2- metastatic breast cancer – comparative effectiveness from a chart review study. Int J Breast Cancer 2015;2015:240750 doi: 10.1155/2015/240750. Epub 2015 May 20.
   PubMedGoogle Scholar
• Carlson RW, Allred DC, Anderson BO, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:821-9
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Breast cancer. Fort Washington, PA: National Comprehensive Cancer Network (NCCN), 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [Last accessed 1 January 2015]
   Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907-22
   PubMed Web of Science ®Google Scholar
• Barrios CH, Sampaio C, Vinholes J, Caponero R. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol 2009;20:1157-62
   PubMed Web of Science ®Google Scholar
• Morimoto L, Coalson J, Mowat F, O’Malley C. Factors affecting receipt of chemotherapy in women with breast cancer. Int J Womens Health 2010;2:107-22
   PubMedGoogle Scholar
• Foster JA, Salinas GD, Mansell D, et al. How does older age influence oncologists’ cancer management? Oncologist 2010;15:584-92
   PubMed Web of Science ®Google Scholar
• Hurria A, Wong FL, Villaluna D, et al. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 2008;26:5386-92
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Cazzaniga ME, Pronzato P, et al. Breast cancer in elderly women: a different reality? Results from the NORA study. Ann Oncol 2007;18:991-6
   PubMed Web of Science ®Google Scholar
• Fasching PA, Decker T, Schneeweis A, et al. Breast cancer treatment with everolimus and exemestane for ER+ women – results of the 2nd interim analysis of the non-interventional trial BRAWO. J Clin Oncol 2014;32(5s Suppl): abstr 578
   PubMed Web of Science ®Google Scholar
• Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-68
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
   PubMed Web of Science ®Google Scholar
• Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91
   PubMed Web of Science ®Google Scholar
• Massarweh S, Romond E, Black EP, et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat 2014;143:325-32
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Bachelot TD, Saletan S, et al. BOLERO-4: multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer. J Clin Oncol 2013;31(Suppl): abstr TPS661
   Google Scholar
• Bent Ejlertsen, Jerusalem GHM, Hurvitz SA, et al. BOLERO-6: phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+, HER2- advanced breast cancer. J Clin Oncol 2013;31(Suppl): abstr TPS660
   Google Scholar
• Yardley DA. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists. Clin Breast Cancer 2014;14:297-308
   PubMed Web of Science ®Google Scholar
• Vassar M, Holzmann M. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof 2013;10:12
   PubMedGoogle Scholar